跳至主要内容
临床试验/EUCTR2017-002383-40-IT
EUCTR2017-002383-40-IT进行中(未招募)1 期

Treatment study for children and adolescents with Acute Promyelocytic Leukemia - ICC APL Study 02

AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica0 个研究点目标入组 90 人开始时间: 2018年10月15日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Newly diagnosed APL confirmed by the presence of PML/RARa fusion gene
  • - Age <18 years
  • - Written informed consent by parents or legal guardians
  • - WBC at diagnosis =10 x 109/L
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 90
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients with a clinical diagnosis of APL but subsequently found to lack PML/RARa rearrangement should be withdrawn from the study and treated with an alternative protocol
  • - Significant liver dysfunction (bilirubin serum levels >3 mg/dL, ALT/AST serum levels greater than 5 times the normal values)
  • - Creatinine serum levels >2 times the normal value for age
  • - Significant arrhythmias, EKG abnormalities (*see below), other cardiac contraindications (L-FEV < 50% or LV-FS <28%)
  • - Neuropathy grade 2 or greater
  • - Concurrent active malignancy
  • - Uncontrolled life-threatening infections
  • - Pregnant or lactating females
  • - Patients who had received alternative therapy (APL not initially suspected; ATRA and/or ATO not available)

研究者

发起方
AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica

相似试验